SCHEMBL176914

SCHEMBL176914

Cc1c(N)cc(S(=O)(=O)O)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 2/20 0.45
NT5E P21589 2/20 0.44
ALDH1A1 P00352 7/20 0.44
HSD17B10 Q99714 4/20 0.44
CASP6 P55212 3/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NSD2 O96028 1/20 0.42
PLCG1 P19174 1/20 0.42
DNMT1 P26358 1/20 0.42
TSHR P16473 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
CYP3A4 P08684 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4812412 0.90 ALDH1A1 (0.52) CASRNT5EALDH1A1HSD17B10CASP6
SCHEMBL11331642 0.88 ALDH1A1 (0.50) CASRNT5EALDH1A1HSD17B10CASP6
SCHEMBL8636120 0.86 CASR (0.47) CASRNT5EALDH1A1HSD17B10CASP6
Acetoacetic Acid SCHEMBL11500881 0.85 CASR (0.47) CASRNT5EALDH1A1HSD17B10CASP6
SCHEMBL6935562 0.80 CASP6 (0.53) NT5EALDH1A1HSD17B10CASP6CYP2C9
SCHEMBL29918476 0.80 NT5E (0.47) NT5EALDH1A1HSD17B10CASP6CYP2C9
SCHEMBL7709568 0.80 NT5E (0.47) NT5EALDH1A1HSD17B10CASP6CYP2C9
SCHEMBL8376960 0.79 CA1 (0.43) ALDH1A1HSD17B10GAAL3MBTL1TSHR
SCHEMBL17262954 0.78 ALDH1A1 (0.60) NT5EALDH1A1HSD17B10CASP6CYP2C9
SCHEMBL9297596 0.78 NT5E (0.46) NT5EALDH1A1HSD17B10CASP6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11137657-A None JP disclosed
EP-3730134-B1 MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS EA PHARMA CO LTD (JP) 2025-05-14 EP disclosed
US-RE49569-E1 Alkylamine derivative EA PHARMA CO., LTD. (JP) 2023-07-04 US disclosed
CN-116332809-A Process for producing alkylamine derivative and intermediate for production thereof 味之素株式会社 2023-06-27 CN disclosed
CN-115536556-A Process for producing alkylamine derivative and intermediate for producing the same 味之素株式会社 2022-12-30 CN disclosed
US-20220142958-A1 MEDICINAL COMPOSITION HAVING EXCELLENT STABILITY EA PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20220142958-A1 MEDICINAL COMPOSITION HAVING EXCELLENT STABILITY EA PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-11311508-B2 Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis EA PHARMA CO., LTD. (JP) 2022-04-26 US disclosed
EP-3950058-A1 PHARMACEUTICAL COMPOSITION HAVING FAVORABLE STABILITY EA Pharma Co., Ltd. (JP) 2022-02-09 EP disclosed
CN-113260416-A Pharmaceutical composition with good stability EA制药株式会社 2021-08-13 CN disclosed
US-4576973-A ADSORBENT BEAD CASSELLA AKTIENGESELLSCHAFT (DE) 1986-03-18 US disclosed
US-4552905-A VINYL-SUBSTITUTED PYRIDINE, QUINOLINE, ISO-QUINOLINE, OR PYRAZINE;N-VINYLAMIDE, CROSSLINKER CASSELLA AKTIENGESELLSCHAFT (DE) 1985-11-12 US disclosed
EP-0134921-A1 Copolymer, process for its preparation and its use as a sorbent CASSELLA Aktiengesellschaft (DE) 1985-03-27 EP disclosed
EP-0073406-B1 WATER-SOLUBLE MONOAZO PYRAZOLONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DYESTUFFS HOECHST AKTIENGESELLSCHAFT (DE) 1985-03-20 EP disclosed
EP-0131179-A1 Copolymer, process for its preparation and its use as a sorbent CASSELLA Aktiengesellschaft (DE) 1985-01-16 EP disclosed
EP-0056975-B1 WATER SOLUBLE MONOAZOCOMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DYESTUFFS HOECHST AKTIENGESELLSCHAFT (DE) 1985-01-16 EP disclosed
EP-0103156-A2 Copper complex of water soluble disazo compounds, process for their preparation and their use as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1984-03-21 EP disclosed
EP-0073406-A1 Water-soluble monoazo pyrazolone compounds, process for their preparation and their use as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1983-03-09 EP disclosed
EP-0056975-A2 Water soluble monoazocompounds, process for their preparation and their use as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1982-08-04 EP disclosed
US-4035350-A Process for the preparation of water-soluble azo dyestuffs by reacting an aromatic amine and a coupling component with alkali metal nitrite or alkyl nitrite in the absence of acid HOECHST AKTIENGESELLSCHAFT (DT) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11311508-B2 Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis PTH1R, PTMS, REN CASR 13/4885NT5E 1869/4885ALDH1A1 3730/4885
US-20220142958-A1 MEDICINAL COMPOSITION HAVING EXCELLENT STABILITY UGT2B7, TPMT, CEL CASR 2569/4885NT5E 3216/4885ALDH1A1 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.